Recombinant Human Melanoma-Associated Antigen 3 (MAGEA3) Protein (His&Myc)

Name: Recombinant Human Melanoma-Associated Antigen 3 (MAGEA3) Protein (His&Myc)
Brand: Beta LifeScience
SKU: BLC-04853P
Availability: InStock

Greater than 85% as determined by SDS-PAGE.

Collections: All products, High-quality recombinant proteins, Other recombinant proteins

Our products are highly customizable to meet your specific needs. You can choose options such as endotoxin removal, liquid or lyophilized forms, preferred tags, and the desired functional sequence range for proteins. Submitting a written inquiry expedites the quoting process.

Submit an inquiry today to inquire about all available size options and prices! Connect with us via the live chat in the bottom corner to receive immediate assistance.

Product Overview

Description	Recombinant Human Melanoma-Associated Antigen 3 (MAGEA3) Protein (His&Myc) is produced by our E.coli expression system. This is a full length protein.
Purity	Greater than 85% as determined by SDS-PAGE.
Uniprotkb	P43357
Target Symbol	MAGEA3
Synonyms	Antigen MZ2 D ; Antigen MZ2-D; Cancer/testis antigen 1.3; Cancer/testis antigen family 1 member 3; CT1.3; HIP8; HYPD; MAGA3_HUMAN; MAGE 3 antigen; MAGE family member A3; MAGE-3 antigen; MAGE3; MAGEA3; MAGEA6; Melanoma antigen family A 3; Melanoma associated antigen 3; Melanoma-associated antigen 3; MGC1461
Species	Homo sapiens (Human)
Expression System	E.coli
Tag	N-10His&C-Myc
Target Protein Sequence	MPLEQRSQHCKPEEGLEARGEALGLVGAQAPATEEQEAASSSSTLVEVTLGEVPAAESPDPPQSPQGASSLPTTMNYPLWSQSYEDSSNQEEEGPSTFPDLESEFQAALSRKVAELVHFLLLKYRAREPVTKAEMLGSVVGNWQYFFPVIFSKASSSLQLVFGIELMEVDPIGHLYIFATCLGLSYDGLLGDNQIMPKAGLLIIVLAIIAREGDCAPEEKIWEELSVLEVFEGREDSILGDPKKLLTQHFVQENYLEYRQVPGSDPACYEFLWGPRALVETSYVKVLHHMVKISGGPHISYPPLHEWVLREGEE
Expression Range	1-314aa
Protein Length	Full Length
Mol. Weight	39.8 kDa
Research Area	Cancer
Form	Liquid or Lyophilized powder
Buffer	Liquid form: default storage buffer is Tris/PBS-based buffer, 5%-50% glycerol. Lyophilized powder form: the buffer before lyophilization is Tris/PBS-based buffer, 6% Trehalose, pH 8.0.
Storage	1. Store at -20°C/-80°C upon receipt, aliquoting is necessary for mutiple use. 2. Avoid repeated freeze-thaw cycles. 3. Store working aliquots at 4°C for up to one week. 4. In general, protein in liquid form is stable for up to 6 months at -20°C/-80°C. Protein in lyophilized powder form is stable for up to 12 months at -20°C/-80°C.
Notes	Repeated freezing and thawing is not recommended. Store working aliquots at 4°C for up to one week.

Target Details

Target Function

Activator of ubiquitin ligase activity of RING-type zinc finger-containing E3 ubiquitin-protein ligases that acts as a as repressor of autophagy. May enhance ubiquitin ligase activity of TRIM28 and stimulate p53/TP53 ubiquitination by TRIM28. Proposed to act through recruitment and/or stabilization of the Ubl-conjugating enzyme (E2) at the E3:substrate complex. May play a role in embryonal development and tumor transformation or aspects of tumor progression. In vitro promotes cell viability in melanoma cell lines. Antigen recognized on a melanoma by autologous cytolytic T-lymphocytes.

Database References

HGNC: 6801

OMIM: 300174

KEGG: hsa:4102

STRING: 9606.ENSP00000359301

UniGene: PMID: 27561960

the objective response rate was lower in this study than in other studies carried out in the same setting with the MAGE-A3 immunotherapeutic. Investigation of a gene signatures (GS) to predict clinical benefit to adjuvant MAGE-A3 immunotherapeutic treatment is ongoing in another melanoma study. PMID: 27502712

Administering autologous CD4(+) T cells that are genetically engineered to express an MHC class II-restricted antitumor TCR that targets MAGE-A3 can be used safely in the treatment of metastatic neoplasms. PMID: 28809608

MAGEA3 may be demethylated in MPNST and plexiform type neurofibroma in NF-1 patients PMID: 27422441

MAGEA3 was overexpressed in colorectal cancer tissue compared with healthy colon. MAGEA3 expression positively correlated with colorectal cancer progression. PMID: 27635108

Comparing the overall expression of CTAs, a decreased expression of all melanoma-associated antigens (MAGEs) post-treatment and a slightly increased expression of New York esophageal squamous cell carcinoma 1 (NY-ESO-1) was visible. The simultaneous cytoplasmic and nuclear expression of pan-MAGE or MAGE-A3/A4 correlated with reduced treatment-failure-free-survival (TFFS). PMID: 27466502

MAGE-A3 expression is regulated epigenetically by promoter methylation, and that its expression contributes to gastric cell proliferation and drug sensitivity. PMID: 26868260

Progression free survival and levels of MAGE-A3 expression in non-small cell lung carcinoma patients with the three modes of acquired resistance are negatively correlated. PMID: 26612451

the crystal structures of MAGE-A3 and MAGE-A4 PMID: 26910052

MAGEA3/6 positivity was associated with significantly better disease-free survival. PMID: 25564441

Anticancer effects of adenovirus-mediated calreticulin and melanoma-associated antigen 3 expression on non-small cell lung cancer cells PMID: 25704851

our findings indicated that MAGE-A3 is a novel cancer stem cell antigen in bladder cancer PMID: 25031712

MAGE-A3 may serve as a potential prognostic marker for clear cell renal cell carcinoma PMID: 25120790

Study describes a widespread mechanism to suppress AMPK through its ubiquitination and degradation by the cancer-specific MAGE-A3/6-TRIM28 ubiquitin ligase. MAGE-A3 and MAGE-A6 are highly similar proteins normally expressed only in the male germline but frequently re-activated in human cancers. PMID: 25679763

MAGE proteins bind to KAP1, a gene repressor and ubiquitin E3 ligase which also binds KRAB domain containing zinc finger transcription factors (KZNFs), and MAGE expression may affect KZNF mediated gene regulation. PMID: 25107531

Study demonstrated that the expression of MAGE-A3/4 antigen might be a valuable prognostic factor regarding survival in patients with NSCLC. PMID: 24675493

Data indicate that MAGE3, Survivin and B-cell maturation antigen (BCMA) mRNA-pulsed dendritic cells (DCs) are capable of stimulating tumor-associated antigens (TAA)-specific T-cell responses in multiple myeloma (MM) patients. PMID: 23728352

Cells bearing either intermediate proteasome present peptides MAGE-A(3114-122) and MAGE-C2(42-50) as efficiently as cells equipped with the immunoproteasome. PMID: 22925930

High MAGE-3 gene expression is associated with metastases in hepatitis C virus patients complicated by hepatocellular carcinoma. PMID: 21452042

the expression of MAGE, as confirmed in the RT-PCR analysis, could be used as an alternative method for the early diagnosis of salivary gland tumours. PMID: 22498264

Report MAGEA1-A6 expression and MAGE A3 methylation in sputum suggests presence of lung cancer cells or precancerous cells. PMID: 22134685

Cancer/testis antigens are novel targets of immunotherapy for adult T-cell leukemia/lymphoma. PMID: 22323448

Data indicate the association of MAGE-A3 expression and poor prognosis in diffuse large B-cell lymphoma (DLBCL) patients. PMID: 22183072

MAGE-A3 gene may have a clinical relevance and important role as a risk factor in the development of acute myeloid leukemia PMID: 21804405

Expression of MAGE I proteins, MAGE-A3 or MAGE-C2, relieved repression of a reporter gene by ZNF382 and MAGE I expression relieved KAP1 mediated ID1 repression. PMID: 21876767

we found that the SSX4 and MAGE-A3 genes are frequently expressed in brain tumor cell lines PMID: 21347689

MAGE-A3 was detected in a significantly higher percentage of relapsed patients compared with newly diagnosed, establishing a novel correlation with progression of disease. PMID: 21565982

MAGE-A3, a cancer-testis antigen, plays an important role in the survival of multiple myeloma cells. PMID: 20015885

Primary tumors with and without lymph node metastases showed no significant differences in MAGE-A 3/4 (P=0.672) and NY-ESO-1 (P=0.444) expression PMID: 21556122

RT-PCR assays of MAGE-A3 and MAGE-A4 in blood of breast cancer (BC) patients may have prognostic and predictive implications, and they are promising specific tumor markers of BC PMID: 21264495

MAGE3 expression mediated by demethylation of MAGE3 promoter induce progression of non-small cell lung cancer. PMID: 21273595

Molecular upstaging of MAGE-A3 using rt-pcr was correlated with prognosis in melanoma patients PMID: 21135695

Report immunohistochemical expression of MAGE-A3 in renal oncocytoma and chromophobe renal cell carcinoma. PMID: 20591578

results showed that MAGE-A3 gene expression was frequent in NHL patients and decreased after effective chemotherapy, suggesting that MAGE-A3 can be used as a tumor marker for circulating lymphoma cells in patients with NHL. PMID: 20036422

Tumor-specific antigen MAGE may play a role in the occurrence and development of ovarian cancer and can be used as one of the important indicators for early diagnosis, efficacy evaluation and prognostic determination of ovarian cancer. PMID: 20423514

MAGE-A3/6 and NY-ESO-1 were expressed in 50.0% (66/132) and 18.2% (24/132) of non-small-cell lung carcinomas, respectively. PMID: 19795170

Identification of immunodominant regions among promiscuous HLA-DR-restricted CD4+ T-cell epitopes on the tumor antigen MAGE-3 PMID: 12393675

This melanoma-associated marker was detected in melanoma cell lines. PMID: 12710945

first evidence that the naturally processed MAGE-3(271-279) can be isolated and identified from the tumor tissue of hepatocellular carcinoma patient PMID: 15885805

The newly identified MAGE-3(113)-peptide epitope is naturally processed and presented as the CTL epitope on MAGE-3-expressing GI cancer cells, indicating that anti-MAGE-3 immune targeting with the MAGE-3(113) peptide is a promising approach for treatment. PMID: 16446550

MAGE-A3 gene mRNA is expressed at the mRNA level in a proportion of human leukemias. PMID: 16806467

The promoter hypomethylation of MAGE-A1 and MAGE-A3 genes up-regulates their expression in colorectal carcinomas as well as in gastric cancers and might play a significant role in the development and progression of human colorectal carcinomas. PMID: 17007017

Gene expression profiling identified the cancer/testis antigen MAGE-A3/6 as a novel target of FGFR2-IIIb signaling. PMID: 17699848

Measurement of Melan-A, gp100, MAGE-3, MIA and tyrosinase represents a prognostic factor and a method for early detection of metastasis and treatment response of melanoma patients. PMID: 18181974

MAGEC1/CT7, MAGEA3/6 and LAGE-1 are good candidates for immunotherapy, since together they cover 85% of our MM cases. PMID: 18237105

the repertoire of MAGE-A3 epitopes recognized in vivo by CD4+ T cells are influenced by endosomal proteases PMID: 18316621

MAGE-A3 as a target of FGFR2-IIIb and estrogen action and provide evidence for a common histone-modifying network in the control of the balance between opposing signals. PMID: 18381936

MAGE-A3 may have a role in melanoma and could be used in a therapeutic vaccine PMID: 18483279

MAGE A3 is a functional integrator of diverse signals, including FGFR2 and FN, to modulate cancer progression. PMID: 18829569

Its expression is significantly associated with prognostic factors in poor outcome of the non-small cell lung cancer PMID: 18982744

FAQs

Please fill out the Online Inquiry form located on the product page. Key product information has been pre-populated. You may also email your questions and inquiry requests to sales1@betalifesci.com. We will do our best to get back to you within 4 business hours.

Feel free to use the Chat function to initiate a live chat. Our customer representative can provide you with a quote immediately.

Proteins are sensitive to heat, and freeze-drying can preserve the activity of the majority of proteins. It improves protein stability, extends storage time, and reduces shipping costs. However, freeze-drying can also lead to the loss of the active portion of the protein and cause aggregation and denaturation issues. Nonetheless, these adverse effects can be minimized by incorporating protective agents such as stabilizers, additives, and excipients, and by carefully controlling various lyophilization conditions.

Commonly used protectant include saccharides, polyols, polymers, surfactants, some proteins and amino acids etc. We usually add 8% (mass ratio by volume) of trehalose and mannitol as lyoprotectant. Trehalose can significantly prevent the alter of the protein secondary structure, the extension and aggregation of proteins during freeze-drying process; mannitol is also a universal applied protectant and fillers, which can reduce the aggregation of certain proteins after lyophilization.

Our protein products do not contain carrier protein or other additives (such as bovine serum albumin (BSA), human serum albumin (HSA) and sucrose, etc., and when lyophilized with the solution with the lowest salt content, they often cannot form A white grid structure, but a small amount of protein is deposited in the tube during the freeze-drying process, forming a thin or invisible transparent protein layer.

Reminder: Before opening the tube cap, we recommend that you quickly centrifuge for 20-30 seconds in a small centrifuge, so that the protein attached to the tube cap or the tube wall can be aggregated at the bottom of the tube. Our quality control procedures ensure that each tube contains the correct amount of protein, and although sometimes you can't see the protein powder, the amount of protein in the tube is still very precise.

To learn more about how to properly dissolve the lyophilized recombinant protein, please visit Lyophilization FAQs.